Browse > Article
http://dx.doi.org/10.14776/piv.2022.29.e6

Delphi Survey for COVID-19 Vaccination in Korean Children Between 5 and 11 Years Old  

Choe, Young June (Department of Pediatrics, Korea University Anam Hospital)
Lee, Young Hwa (Allergy Immunology Center, Korea University)
Choi, Jae Hong (Department of Pediatrics, Jeju National University School of Medicine)
Publication Information
Pediatric Infection and Vaccine / v.29, no.1, 2022 , pp. 37-45 More about this Journal
Abstract
Purpose: During the coronavirus disease 2019 (COVID-19) pandemic, we conducted a Delphi survey that included the experts from the field of COVID-19 immunization in children aged 5-11 years. The aim was to organize collective expert opinions on COVID-19 vaccination in young children in the Republic of Korea, and so thus assist the vaccination policy. Methods: The panels included pediatric infectious disease specialists, preventive medicine experts, infectious disease physicians, and COVID-19 vaccine experts consulting the Ministry of Health and Welfare. The Delphi survey was conducted online using a questionnaire from February 14 to February 27, 2022. Results: The Delphi panels agreed that children were vulnerable to COVID-19, and the severity of illness was modest. Furthermore the panels reported that children with chronic illness were more susceptible to a worsening clinical course. There were generally positive opinions on the effectiveness of COVID-19 vaccination in children aged 5-11 years, and experts gathered a slightly positive opinion that the adverse events of pediatric COVID-19 were not numerous. The benefits of COVID-19 vaccination were evaluated at a level similar to the potential risks in children. Currently, the only approved mRNA platform vaccine in children seemed to be sustainable; however, the recombinant protein platform COVID-19 vaccines were evaluated as better options. Conclusions: Due to the surge of the Omicron variant and an increase in pediatric cases, the COVID-19 vaccination in young children may have to be considered. Panels had neutral opinions regarding the COVID-19 vaccination in children aged 5-11 years. Thus monitoring of the epidemiology and the data about the safety of COVID-19 vaccination should be continued.
Keywords
COVID-19; Vaccine; Children; Delphi technique;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Viner R, Waddington C, Mytton O, Booy R, Cruz J, Ward J, et al. Transmission of SARS-CoV-2 by children and young people in households and schools: a meta-analysis of population-based and contact-tracing studies. J Infect 2022;84:361-82.   DOI
2 Fowlkes AL, Yoon SK, Lutrick K, Gwynn L, Burns J, Grant L, et al. Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5-11 years and adolescents aged 12-15 years - PROTECT cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep 2022;71:422-8.   DOI
3 Hause AM, Baggs J, Marquez P, Myers TR, Gee J, Su JR, et al. COVID-19 vaccine safety in children aged 5-11 years - United States, November 3-December 19, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1755-60.   DOI
4 World Health Organization. Coronavirus (COVID-19) dashboard with vaccination data [Internet]. Geneva: World Health Organization; 2022 [cited 2022 Mar 21]. Available from: https://covid19.who.int/.
5 Balicer RD, Ohana R. Israel's COVID-19 endgame. Science 2021;372:663.   DOI
6 Korea Disease Control and Prevention Agency. Coronavirus disease 2019 (COVID-19) [Internet]. Cheongju: Korea Disease Control and Prevention Agency; 2022 [cited 2022 Apr 4]. Available from: http://ncov.mohw.go.kr/.
7 Clyne B, Jordan K, Ahern S, Walsh KA, Byrne P, Carty PG, et al. Transmission of SARS-CoV-2 by children: a rapid review, 30 December 2019 to 10 August 2020. Euro Surveill 2022;27:2001651.
8 Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, et al. BNT162b2 protection against the omicron variant in children and adolescents. N Engl J Med, in press 2022.
9 Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med 2022;386:35-46.   DOI
10 Carreno JM, Alshammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 2022;602:682-8.   DOI
11 Woodworth KR, Moulia D, Collins JP, Hadler SC, Jones JM, Reddy SC, et al. The advisory committee on immunization practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years - United States, November 2021. MMWR Morb Mortal Wkly Rep 2021;70:1579-83.   DOI
12 Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 2018;17:261-79.   DOI
13 Irfan O, Li J, Tang K, Wang Z, Bhutta ZA. Risk of infection and transmission of SARS-CoV-2 among children and adolescents in households, communities and educational settings: a systematic review and meta-analysis. J Glob Health 2021;11:05013.   DOI
14 Chou J, Thomas PG, Randolph AG. Immunology of SARS-CoV-2 infection in children. Nat Immunol 2022;23:177-85.   DOI